Navigation Links
Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway
Date:9/16/2009

HEIDELBERG, Germany, September 16 /PRNewswire/ --

- Integrated Chemical Genetics and Proteomics Approach Identifies new Potential Drug Targets in Wnt Pathway

Cellzome announces today, the publication entitled "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling"** is now available online in Nature.

The paper describes how Cellzome's quantitative chemical proteomics platform was used to identify a small molecule which plays a critical role in the regulation of the Wnt pathway. The small molecule stabilizes axin by inhibiting the poly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2. Both tankyrase isoforms interact with a highly conserved domain of axin and stimulate its degradation through the ubiquitin-proteasome pathway. Thus, the study provides new mechanistic insights into the regulation of axin protein homeostasis and presents new avenues for therapeutic intervention in this key cancer pathway. This transforming science was conducted as part of the collaboration between Cellzome and Novartis Institutes for Biomedical Research (NIBR).

Dr. David Simmons, CSO of Cellzome, said: "This paper shows the powerful insights provided by Cellzome's proprietary chemical proteomics technology platform. Our platform also includes Kinobeads(TM) which we use for the discovery and development of a new generation of kinase inhibitors and Episphere(TM) for the discovery of novel drug candidates for epigenetic targets."

** Huang, S., et.al. "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling", Nature, 10.1038/nature08356, 2009.

About Cellzome Inc.

Cellzome is a privately-owned drug discovery and development company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads(TM), a proprietary technology for the screening and profiling of kinase inhibitors in physiologically-relevant cells and tissues. The most advanced program, targeting PI3K(gamma), is anticipated to enter the clinic in 2010, and several other programs are in early preclinical testing.

Cellzome is expanding its distinctive technology, in a novel form called Episphere(TM), to the discovery and development of novel drug candidates for epigenetic targets in their protein complexes.

Cellzome has significant collaborations with GSK and Johnson & Johnson. Its holding company is domiciled in the US and it employs about 90 people at its two laboratories in Cambridge, UK and Heidelberg, Germany.


'/>"/>
SOURCE Cellzome Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
2. Abbott Wins Top Honor in Wall Street Journal Technology Innovation Awards
3. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
4. China Agro-Technology Holdings Announces Launch of Agricultural Biotech Website
5. Dr M Group Selects Health Robotics Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia
6. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
7. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
8. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
9. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
10. Tata Interactive Systems Initiates Vertical-Focused Learning Solutions for Health Care, Pharmaceutical, and Biotechnology
11. Hyland Software Provides Grant Assistance to Kick-Start Technology Projects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS ... the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US ... absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first-ever genomics analysis platform specifically designed for life science researchers to analyze ... pioneering researcher Rosalind Franklin, who made a major contribution to the discovery ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... ... , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. The ... Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, industry ... officials from around the world to address key issues in device compliance, quality and ...
Breaking Biology Technology:
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):